Agreements reached under this partnership
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社ナティアス |
| Alliance partner's business activities | Manufacture and sale of nucleic acid active pharmaceutical ingredients and other products based on long-chain nucleic acid synthesis technology |
| Alliance partner's location | Kobe, Hyogo Prefecture |
| Acquisition price | Investment amount undisclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company determined that 株式会社ナティアス has strong global competitive advantages in its proprietary "Blockmer®" technology and a track record of being selected for national projects and other initiatives, and that the company has a high degree of compatibility with the Group's Gateway model, which aims to enhance corporate value by connecting outstanding Japanese technologies with overseas capital and global networks.